Table 1—

Demographics and baseline clinical characteristics (intent-to-treat population)

OmalizumabPlacebo
Sex % male5147
Mean age yrs40 (12–76)39 (12–72)
Mean duration of asthma yrs20.3 (2–68)19.1 (1–63)
Mean BDP dose µg·day−1769 (500–1600)772 (200–2000)
Mean serum total IgE IU·mL−1223 (21–785)206 (22–814)
Mean FEV1 % pred70 (30–112)70 (22–109)
Severe asthma n (%)#60 (22)59 (22)
Mean AQLQ domain scores
 Activities4.41 (1.27–7.00)4.36 (1.67–6.82)
 Emotions+4.76 (1.40–7.00)4.65 (1.00–7.00)
 Symptoms§4.47 (1.45–6.70)4.39 (2.00–6.42)
 Environmental exposureƒ4.48 (1.00–7.00)4.25 (1.00–7.00)
 Overall score##4.43 (1.58–6.48)4.36 (1.84–6.38)
  • Data are presented with range in parentheses unless otherwise stated. Omalizumab n=274, placebo n=272

  • BDP: beclomethasone dipropionate

  • IgE: immunoglobulin E

  • IU: International Units

  • FEV1: forced expiratory volume in one second

  • % pred: % predicted

  • AQLQ: Asthma Quality of Life Questionnaire

  • #: baseline FEV1 ≤65% pred and a mean total symptom score of >4 for the last 2 weeks of the run-in period

  • : omalizumab n=258, placebo n=251

  • +: omalizumab n=221, placebo n=212

  • §: omalizumab n=222, placebo n=212

  • ƒ: omalizumab n=222, placebo n=211

  • ##: omalizumab n=257, placebo n=251